VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2020 | BTK inhibtors in CLL

Richard Furman, MD, of the Weill Cornell Medical College, New York, NY, updates us on the use of BTK inhibitors in the treatment of chronic lymphocytic leukemia (CLL) as well as the development of third-generation BTK inhibitors that are currently in Phase II studies. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter